Update information

Update information

November 2017: Footnotes for some recommendations were updated with current UK marketing authorisations and MHRA advice. Cross-references to other guidelines that have been superseded since original publication have been updated. Some research recommendations have been stood down.

February 2016: The Medicines and Healthcare Products Regulatory Agency (MHRA) has produced a toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy. Healthcare professionals are advised to use the NICE guideline in conjunction with the latest MHRA advice and resources. Footnotes have been added to the guideline to link to the MHRA's latest advice and resources.

April 2015: Recommendations 1.5.5, 1.5.8 and 1.7.6 have had links to section 1.10 added. Recommendations in section 1.10 related to valproate have been reordered, and a new recommendation on withdrawal of valproate in women of childbearing potential added. These changes are in line with the revised Medicines and Healthcare Products Regulatory Agency (MHRA) warning on valproate.

January 2015: The Medicines and Healthcare Products Regulatory Agency (MHRA) has strengthened its warnings on the use of valproate in women of childbearing potential.

ISBN: 978‑1‑4731‑0721‑2

  • National Institute for Health and Care Excellence (NICE)